Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury.
Products | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Integrin | Products > Signaling Pathways > Transmembrane Glycoprotein
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.